ELA026 clinical trials

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

This study is testing a new medicine called ELA026 for a rare and serious immune condition called secondary Hemophagocytic Lymphohistiocytosis (sHLH). We want to see how safe and effective it is, and how it works in the body, for people with sHLH.